Thermo Fisher Scientific Inc. (TMO) Shares Sold by Groesbeck Investment Management Corp NJ

Groesbeck Investment Management Corp NJ reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.4% during the first quarter, Holdings Channel reports. The institutional investor owned 3,495 shares of the medical research company’s stock after selling 200 shares during the period. Groesbeck Investment Management Corp NJ’s holdings in Thermo Fisher Scientific were worth $957,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc increased its position in shares of Thermo Fisher Scientific by 1.2% in the third quarter. Vanguard Group Inc now owns 29,271,095 shares of the medical research company’s stock worth $7,144,489,000 after purchasing an additional 347,836 shares during the last quarter. BlackRock Inc. increased its position in shares of Thermo Fisher Scientific by 3.7% in the fourth quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock worth $5,858,214,000 after purchasing an additional 944,035 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Thermo Fisher Scientific by 44,296.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after purchasing an additional 19,521,889 shares during the last quarter. FMR LLC increased its position in shares of Thermo Fisher Scientific by 33.4% in the fourth quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 4,897,714 shares of the medical research company’s stock worth $1,094,013,000 after purchasing an additional 422,625 shares during the last quarter. 88.39% of the stock is currently owned by institutional investors.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 5,400 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the transaction, the senior vice president now directly owns 31,846 shares in the company, valued at $8,009,587.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 50,713 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the transaction, the chief executive officer now owns 302,193 shares in the company, valued at $82,562,149.53. The disclosure for this sale can be found here. Insiders have sold 81,720 shares of company stock worth $21,763,423 over the last quarter. Company insiders own 0.45% of the company’s stock.

Shares of NYSE TMO opened at $261.73 on Monday. Thermo Fisher Scientific Inc. has a one year low of $202.83 and a one year high of $282.98. The company has a current ratio of 1.69, a quick ratio of 1.16 and a debt-to-equity ratio of 0.61. The company has a market cap of $104.69 billion, a price-to-earnings ratio of 23.54, a price-to-earnings-growth ratio of 1.72 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.07. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The business had revenue of $6.13 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the business earned $2.50 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.19 EPS for the current fiscal year.

Several research analysts recently weighed in on TMO shares. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Deutsche Bank upped their price objective on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $270.00 to $288.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $312.00 price objective (up from $271.00) on shares of Thermo Fisher Scientific in a research report on Monday, April 22nd. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $293.77.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc. (TMO) Shares Sold by Groesbeck Investment Management Corp NJ” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/05/20/thermo-fisher-scientific-inc-tmo-shares-sold-by-groesbeck-investment-management-corp-nj.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.